Core Viewpoint - Biomerica, Inc. has appointed Eric B. Chin to its Board of Directors, enhancing its corporate governance and financial oversight as it scales commercialization efforts for its diagnostic and therapeutic products [1][7]. Group 1: Appointment Details - Eric B. Chin has been appointed as Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee and the Compensation Committee, effective June 4, 2025 [1]. - Chin replaces Cathy Coste, whose resignation was not due to any disagreement with the company [3]. Group 2: Eric B. Chin's Background - Chin is an accomplished financial executive with over 20 years of experience in public and private healthcare organizations [2][7]. - He currently serves as CFO of Akido Labs, where he successfully raised $60 million in recent financing [2][7]. - His previous roles include executive positions at Astrana Health, Public Storage, and Alexandria Real Estate Equities, and he began his career at Ernst & Young LLP [2]. Group 3: Company Overview - Biomerica, Inc. develops, patents, manufactures, and markets advanced diagnostic and therapeutic products aimed at enhancing health and reducing healthcare costs, primarily focusing on gastrointestinal and inflammatory diseases [4]. - The company's inFoods IBS test assesses patients' immunoreactivity to specific foods, providing targeted dietary recommendations to alleviate IBS symptoms [5].

Core Insights - Biomerica, Inc. announced the publication of pivotal clinical trial data for its inFoods IBS test in the June 2025 issue of Gastroenterology, highlighting its significance in treating Irritable Bowel Syndrome (IBS) [1][7] Group 1: Clinical Trial Results - The randomized, multicenter, double-blind, placebo-controlled trial involved 238 patients and showed statistically significant improvement in IBS symptoms, particularly abdominal pain and bloating, when following a personalized elimination diet guided by the inFoods IBS test [2][3] - 59.6% of patients in the treatment group achieved the FDA responder definition for abdominal pain reduction, compared to 42.2% in the control group [8] - Among patients with IBS-C, 67.1% in the treatment arm reached this benchmark versus 35.8% in controls, and for IBS-M patients, 66.0% in the treatment group met the target compared to 29.5% in controls [8] Group 2: Test Methodology and Validation - The inFoods IBS test utilizes a proprietary assay to measure each patient's immune response to specific foods, designed specifically for IBS patients, and is clinically validated [5][10] - The test identifies dietary triggers that may alleviate IBS symptoms, offering a data-driven approach to managing complex dietary restrictions [6][10] Group 3: Market Implications - The inFoods IBS test could be particularly beneficial for IBS-M patients, who represent approximately 33% of the IBS market and currently have no FDA-approved drug treatments available [4][7] - The publication in a high-impact journal reinforces the scientific rigor and clinical impact of the inFoods IBS approach, marking a significant milestone in precision nutrition as a non-drug treatment pathway for IBS [3][7]